EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Universal Tumor Screening in Colorectal Cancer: Role of MMR Immunohistochemistry for Lynch Syndrome and Early-Onset CRC

Silvia Negro iD, Sara Lessio, Daniele Passeri iD, Andrea Baldo, Marco Scarpa, Angelo Paolo Dei Tos, Ganmaria Pennelli, Francesca Schiavi, Claudia Pinato iD, Matteo Fassan iD, Quoc Riccardo Bao iD, Francesca Bergamo und 3 weitere

Cancers · 08.08.2026 · 18 (16) · 2549

DOI: 10.3390/cancers18162549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.08.2026. Verfasst von Silvia Negro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Third Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35128 Padua, Italy. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mismatch repair deficiency (MMRd) is a central molecular determinant of colorectal cancer (CRC) biology, prognosis, and treatment response, and Universal Tumour Screening (UTS) is advocated for Lynch syndrome (LS) detection; yet real-world performance across clinical subgroups remains limited. We evaluated MMRd distribution and UTS-based LS detection in a large consecutive surgical cohort.

Methods

We retrospectively analyzed 1022 consecutive CRC patients undergoing surgical resection at the University Hospital of Padua (2015–2023). MMR status was assessed by immunohistochemistry; MMRd cases underwent reflex BRAF mutation testing and, when available, MLH1 promoter methylation analysis, followed by germline multigene panel testing for suspected LS. Clinicopathological features were compared by MMR status, age at onset, and tumour location.

Results

MMR testing was performed in 875 patients (85.6%), rising from 67.0% (2015–2017) to 97.4% (2021–2023). MMRd was identified in 139 tumors (15.9%) and was independently associated with age ≥ 70 years, colonic location, and stage 0–II. Of 22 patients with confirmed LS, 13 (59.1%) were newly identified through UTS; family history showed no significant univariate association with LS status and was not independently associated with MMRd after multivariable adjustment. MMRd prevalence was numerically higher in early- than late-onset CRC (20.0% vs. 15.4%), approaching significance after multivariable adjustment (OR 1.90, 95% CI 0.99–3.64; p = 0.054); hereditary syndromes were also more frequent in early-onset disease. MMRd was markedly rarer in rectal than colonic cancer (4.1% vs. 22.5%; p < 0.0001), though MMRd rectal cancers arose in younger patients.

Conclusions

UTS identified a substantial proportion of LS carriers missed by age- or family-history criteria. The relationship between age and MMRd prevalence proved more nuanced than a simple comparison would suggest, reinforcing the value of universal over selective testing across the age spectrum, while MMRd rectal cancer shows a distinct younger profile relevant to immunotherapy-based organ preservation.

Schlagwörter

Stichwörter der Autor:innen

Lynch syndromecolorectal cancerearly-onset colorectal cancermismatch repair deficiencyuniversal tumor screening

Autor:innen und Institutionen

  • Third Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35128 Padua, Italy.
  • Surgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics, Azienda Ospedale-Università Padova, 35124 Padua, Italy.
  • Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology-Scientific Institute for Research, Hospitalization and Health Care, IOV-IRCCS, 35128 Padua, Italy.
  • Medical Oncology Unit 1, Veneto Institute of Oncology-Scientific Institute for Research, Hospitalization and Health Care, IOV-IRCCS, 35128 Padua, Italy.

ORCID-Profile: Silvia Negro, Daniele Passeri, Claudia Pinato, Matteo Fassan, Quoc Riccardo Bao, Sara Lonardi, Gaya Spolverato, Emanuele Damiano Luca Urso

Zitieren

APA

Negro, S., Lessio, S., Passeri, D., Baldo, A., Scarpa, M., Tos, A. P. D., Pennelli, G., Schiavi, F., Pinato, C., Fassan, M., Bao, Q. R., Bergamo, F., Lonardi, S., Spolverato, G., & Urso, E. D. L. (2026). Universal Tumor Screening in Colorectal Cancer: Role of MMR Immunohistochemistry for Lynch Syndrome and Early-Onset CRC. Cancers, 18(16), 2549. https://doi.org/10.3390/cancers18162549

Vancouver

Negro S, Lessio S, Passeri D, Baldo A, Scarpa M, Tos APD, et al. Universal Tumor Screening in Colorectal Cancer: Role of MMR Immunohistochemistry for Lynch Syndrome and Early-Onset CRC. Cancers. 2026;18(16):2549. doi:10.3390/cancers18162549

BibTeX
@article{Negro2026,
  author = {Negro, Silvia and Lessio, Sara and Passeri, Daniele and Baldo, Andrea and Scarpa, Marco and Tos, Angelo Paolo Dei and Pennelli, Ganmaria and Schiavi, Francesca and Pinato, Claudia and Fassan, Matteo and Bao, Quoc Riccardo and Bergamo, Francesca and Lonardi, Sara and Spolverato, Gaya and Urso, Emanuele Damiano Luca},
  title = {Universal Tumor Screening in Colorectal Cancer: Role of MMR Immunohistochemistry for Lynch Syndrome and Early-Onset CRC},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2549},
  doi = {10.3390/cancers18162549}
}
Kostenlos starten →